Alectinib Myths: — Is ALK-Positive Cancer 'Curable'?

Alectinib has cured my cancer — my scans are completely clear

Clear scans show the cancer has responded well to treatment, which is a genuinely significant result. They do not show that every cancer cell has been eliminated — NCCN and ESMO describe the aim as sustained disease control, not eradication. The confusion is understandable: a tumour that shrinks from several centimetres to invisibility on a scan looks and feels resolved. The reason treatment continues is that the evidence consistently shows stopping when scans clear leads to rapid return of the disease.

Alectinib is just chemotherapy with a different name

Alectinib is a targeted kinase inhibitor, not chemotherapy. It works by blocking the ALK fusion protein that is driving growth in your specific tumour. Chemotherapy attacks all rapidly dividing cells in the body, which is why it causes hair loss, mouth sores, and severe fatigue that alectinib generally does not. People often assume all cancer medicines work the same way — both are drugs for cancer, but they act through completely different mechanisms and have substantially different day-to-day effects.

Once alectinib stops working, there is nothing left to try

Resistance to alectinib does not mean the end of treatment options. When alectinib is no longer controlling the disease, your oncologist will reassess — often including a repeat biopsy to understand how the tumour has changed — and discuss next steps with you. The belief that alectinib is a final option is common partly because it is described as a precision treatment, which can sound like the last available answer. In practice, it is usually one step in a sequence your team plans around your cancer's behaviour.

Alectinib works for all lung cancers

Alectinib is effective only in lung cancers confirmed to carry an ALK gene rearrangement, which affects a minority of all lung cancers. Before starting alectinib, your oncologist will have established this through biomarker testing on your tumour tissue. The myth persists partly because news coverage of ALK-targeted therapy rarely emphasises how specific the eligibility is — it reports on a treatment for lung cancer, which sounds universally applicable. It is reasonable to ask what your own test result showed.

ALK-positive cancer must be a mild or slow-moving cancer — otherwise targeted therapy would not work

A good response to targeted therapy does not mean the cancer is less serious or slower moving. ALK-positive NSCLC can spread and progress like any lung cancer if treatment fails or stops. Where outcomes compare favourably to ALK-negative disease treated with chemotherapy alone, NCCN and ESMO attribute this to the effectiveness of ALK inhibitors against this specific driver — not to a gentler underlying biology. The confusion often comes from clinical trial response data, which can make ALK-positive cancer sound inherently manageable in the abstract.